Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2002

View Archived Issues

IL-7, a potentially therapeutic cytokine for IPF

CVT-124 and furosemide preserve renal function and promote natriuresis in heart failure

Anticancer drug DTS-101 in late preclinical development

Genelabs and University of Iowa research the impact of hepatitis G on HIV infection

Zomig RM approved in Japan

Hemosol updates progress of Hemolink

Smallpox vaccine enters phase I trial

CP-248 shows potent activity against rat and human CNS cancer cell lines

Potential efficacy of the selective proteasome inhibitor PS-519 as a treatment for psoriasis

First live diagnostic test for mad cow and Creutzfeldt-Jakob disease

MorViva completes phase II study ahead of schedule

Neurocrine and Wyeth extend EAAT-3 collaboration

ACP-HIP approaches clinical testing

Go-ahead for phase II pilot study of CT-3 in chronic neuropathic pain

Avicine set to enter phase III in pancreatic cancer

TNX-901 increases symptom threshold to peanuts in phase II allergy study

Oxford GlycoSciences reports 36-month data from Vevesca study in Gaucher's disease

Initial stage completed in phase III trial of Tarceva in pancreatic cancer

Patient enrollment begins in pivotol Phase III Oncophage for melanoma study

Inex releases positive interim results for Onco TCS in small cell lung cancer trial

Novel peptides with calcium channel blocking activity reported by Suntory

Medinox designs a new class of modified NSAIDs with improved side effect profile

Japan Science and Technology patents new antibacterial compounds active against MRSA and VRE

New antibacterial compounds prepared by researchers at Kinki University

Japanese researchers identify new, potent and selective antifungal compounds

CancerVax puts hold on new patient enrollment in Canvaxin trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...